HEMISPHERIAN

Redefining treatment for aggressive cancers through TET2-targeted therapeutics

Hemispherian is a Norwegian pharmaceutical company developing a first-in-class class of small-molecule drugs (GLIX) that activate the DNA damage response by restoring TET2 activity. This highly selective mechanism induces double-stranded DNA breaks and apoptosis only in cancer cells, offering a promising new approach for hard-to-treat malignancies.

The lead candidate, GLIX1, is advancing toward clinical development for glioblastoma multiforme (GBM), a devastating cancer of the central nervous system with urgent unmet need. GLIX1 has demonstrated potent anti-tumor activity, excellent blood–brain barrier penetration, and a favorable safety profile, and has received Orphan Drug Designation from both the FDA and EMA.

To accelerate development, Hemispherian has established a joint venture with BioLineRx Ltd., which contributes clinical development and regulatory leadership. The JV will advance GLIX1 into a Phase 1/2a clinical study, following FDA IND clearance, with first-in-human dosing expected in early 2026. The partnership also gives the JV first access to additional molecules in Hemispherian’s pipeline.

Hemispherian is headquartered in Oslo, Norway.

More information: https://hemispherian.com